Marion van Mackelenbergh Selected Research

Therapeutics

1/2023	Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial.
2/2021	A Giant Mammary Hamartoma in a Young Breast Cancer Patient.
1/2021	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
12/2020	Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
1/2020	MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
1/2020	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial.
1/2019	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
1/2019	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
1/2018	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
6/2016	Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marion van Mackelenbergh Research Topics

Disease

24	Breast Neoplasms (Breast Cancer) 02/2024 - 10/2013
12	Neoplasms (Cancer) 11/2023 - 10/2013
6	Triple Negative Breast Neoplasms 10/2021 - 01/2018
5	Pathologic Complete Response 11/2023 - 01/2021
1	Lymphatic Metastasis 02/2024
1	Amenorrhea 01/2021
1	Cardiotoxicity 12/2020
1	Hypoxia (Hypoxemia) 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 01/2020
1	Ovarian Neoplasms (Ovarian Cancer) 03/2018
1	Fatigue 01/2017
1	Ovarian Epithelial Carcinoma 10/2016
1	Carcinogenesis 10/2016
1	Carcinoma (Carcinomatosis) 06/2016
1	Neoplasm Metastasis (Metastasis) 07/2015

Drug/Important Bio-Agent (IBA)

6	Hormones (Hormone)IBA 02/2023 - 07/2015
4	Phenobarbital (Luminal)FDA Link 11/2023 - 01/2018
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2020
2	Estrogen ReceptorsIBA 02/2023 - 01/2022
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 12/2020
2	ErbB Receptors (EGF Receptor)IBA 10/2022 - 03/2018
2	Carboplatin (JM8)FDA LinkGeneric 12/2020 - 01/2020
2	human ERBB2 proteinIBA 01/2019 - 10/2018
2	LigandsIBA 01/2019 - 03/2018
1	Epidermal Growth Factor (EGF)IBA 02/2023
1	Progesterone Receptors (Progesterone Receptor)IBA 02/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Messenger RNA (mRNA)IBA 01/2021
1	durvalumabIBA 01/2021
1	Troponin T (Troponin T1)IBA 12/2020
1	Hemoglobins (Hemoglobin)IBA 12/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2020
1	Epirubicin (Ellence)FDA LinkGeneric 12/2020
1	pro-brain natriuretic peptide (1-76)IBA 12/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020
1	Temozolomide (Temodar)FDA LinkGeneric 01/2020
1	Bevacizumab (Avastin)FDA Link 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2019
1	ParaffinIBA 01/2019
1	erucylphosphocholineIBA 01/2019
1	130-nm albumin-bound paclitaxelIBA 01/2019
1	Formaldehyde (Formol)FDA Link 01/2019
1	MicroRNAs (MicroRNA)IBA 10/2018
1	Metalloproteases (Metalloproteinases)IBA 03/2018
1	PlatinumIBA 03/2018
1	AmphiregulinIBA 03/2018
1	DisintegrinsIBA 03/2018
1	Cisplatin (Platino)FDA LinkGeneric 03/2018
1	antineoplaston A10 (A 10)IBA 01/2018
1	CytokinesIBA 07/2017
1	Phosphotransferases (Kinase)IBA 10/2016
1	Progesterone FDA LinkGeneric 06/2016
1	Aldo-Keto ReductasesIBA 06/2016
1	Nucleic AcidsIBA 10/2013

Therapy/Procedure

10	Neoadjuvant Therapy 12/2023 - 01/2018
10	Therapeutics 01/2023 - 06/2016
4	Drug Therapy (Chemotherapy) 01/2021 - 01/2018
2	Radiotherapy 02/2024 - 02/2021
1	Heterologous Transplantation (Xenotransplantation) 01/2022
1	Mammaplasty (Breast Reconstruction) 02/2021
1	Immunotherapy 01/2019
1	Combination Drug Therapy (Combination Chemotherapy) 01/2018
1	Lymph Node Excision (Lymph Node Dissection) 01/2017
1	Segmental Mastectomy (Lumpectomy) 07/2015